What is it about?
Cushing’s syndrome secondary to paraneoplastic syndrome in EGFR positive adenocarcinoma of lung.
Featured Image
Why is it important?
It shows a case of good clinical and laboratory response to use of osilodrostat, an inhibitor of endogenous cortisol, in a patient with adrenocorticotropic hormone (ACTH)-dependent hypercortisolism due to non-small cell lung cancer.
Perspectives
osilodrostat was approved for ACTH-dependent due to pituitary dysfunction. Here we presented a successfull off label use of this medication.
Caio Heleno
University of Louisville
Read the Original
This page is a summary of: Cushing’s Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat, Case Reports in Oncology, March 2023, Karger Publishers,
DOI: 10.1159/000527824.
You can read the full text:
Resources
Contributors
The following have contributed to this page
